Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3ADGP)

• Drug Name: Rhucin Drug Info
• Synonyms: sildenafil; 139755-83-2; VIAGRA; Sildenafil [INN:BAN]; UK-92480; UNII-3M7OB98Y7H; UK-92,480-10; C22H30N6O4S; HSDB 7305; CHEMBL192; UK 92480-10; CHEBI:9139; 3M7OB98Y7H; 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine; BNRNXUUZRGQAQC-UHFFFAOYSA-N; 5-(2-Ethoxy-5-((4-methylpiperazin-1-yl)sulfonyl)phenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; Sildenafil

Indication

Disease Entry	ICD 11	Status	REF
Erectile dysfunction	HA01.1	Approved	[1] , [2]
Hereditary angioedema	4A00.14	Approved	[3] , [4]

• Cross-matching ID:
  PubChem CID: 135398744
  ChEBI ID: CHEBI:9139
  CAS Number: CAS 139755-83-2
  TTD Drug ID: DM3ADGP
  VARIDT Drug ID: DR00565
  ACDINA Drug ID: D00622

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 5A (PDE5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tadalafil	DMJZHT1	Erectile dysfunction	HA01.1	Approved	[9]
Udenafil	DM1IQRP	Erectile dysfunction	HA01.1	Approved	[10]
Vardenafil	DMTBGW8	Erectile dysfunction	HA01.1	Approved	[11]
Dipyridamole	DMXY30O	Hypertension	BA00-BA04	Approved	[12]
Papaverine	DMCA9QP	Spasm	MB47.3	Approved	[13]
Avanafil	DM75CXN	Erectile dysfunction	HA01.1	Approved	[14]
ICARIIN	DMOJQGT	N. A.	N. A.	Phase 3	[15]
EXISULIND	DMBY56U	Colorectal cancer	2B91.Z	Phase 3	[16]
PF-489791	DM3C8GQ	Chronic obstructive pulmonary disease	CA22	Phase 2	[17]
UK-371800	DMI8795	Erectile dysfunction	HA01.1	Phase 1	[18]

Drug(s) Targeting C1 esterase inhibitor (SERPING1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cinryze	DMVIKJZ	Hereditary angioedema	4A00.14	Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C1 esterase inhibitor (SERPING1)	TTVQ6R9	IC1_HUMAN	Modulator	[3] , [4]
Phosphodiesterase 5A (PDE5A)	TTJ0IQB	PDE5A_HUMAN	Inhibitor	[5] , [6] , [7] , [8]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4743).
• [2] Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs. 2007 Sep;12(3):367-88.
• [3] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [4] Recombinant human c1 inhibitor (conestat alfa): in the treatment of angioedema attacks in hereditary angioedema. BioDrugs. 2012 Oct 1;26(5):315-23.
• [5] cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
• [6] Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. Urology. 2002 Sep;60(2 Suppl 2):49-57.
• [7] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [8] Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res. 2002 Dec;14(6):466-71.
• [9] Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
• [10] Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
• [11] The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
• [12] Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
• [13] Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [15] Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
• [16] Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
• [17] Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
• [18] Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6033-6.
• [19] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.